Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2016 - 2023)

Spyre Therapeutics' Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $360000.0 for Q2 2023.

  • For Q2 2023, Depreciation & Amortization (CF) fell 4.76% year-over-year to $360000.0; the TTM value through Mar 2024 reached $360000.0, down 76.74%, while the annual FY2023 figure was $744000.0, 52.52% down from the prior year.
  • Depreciation & Amortization (CF) reached $360000.0 in Q2 2023 per SYRE's latest filing, down from $384000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $412000.0 in Q3 2021 to a low of $100000.0 in Q1 2019.
  • Average Depreciation & Amortization (CF) over 5 years is $294500.0, with a median of $364500.0 recorded in 2020.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 248.11% in 2020, then dropped 6.33% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $106000.0 in 2019, then surged by 248.11% to $369000.0 in 2020, then rose by 11.38% to $411000.0 in 2021, then decreased by 6.33% to $385000.0 in 2022, then decreased by 6.49% to $360000.0 in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Depreciation & Amortization (CF) are $360000.0 (Q2 2023), $384000.0 (Q1 2023), and $385000.0 (Q4 2022).